These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 15225731)

  • 1. Synthesis and biological evaluation of the major metabolite of atomoxetine: elucidation of a partial kappa-opioid agonist effect.
    Creighton CJ; Ramabadran K; Ciccone PE; Liu J; Orsini MJ; Reitz AB
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4083-5. PubMed ID: 15225731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and SAR study of opioid receptor ligands: mono- and bis-indolomorphinans.
    Li F; Yin C; Chen J; Liu J; Xie X; Zhang A
    Chem Biol Drug Des; 2009 Oct; 74(4):335-42. PubMed ID: 19691470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2006 Jan; 49(1):256-62. PubMed ID: 16392810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.
    Kumar V; Guo D; Cassel JA; Daubert JD; Dehaven RN; Dehaven-Hudkins DL; Gauntner EK; Gottshall SL; Greiner SL; Koblish M; Little PJ; Mansson E; Maycock AL
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1091-5. PubMed ID: 15686919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
    Dolle RE; Michaut M; Martinez-Teipel B; Seida PR; Ajello CW; Muller AL; DeHaven RN; Carroll PJ
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3647-50. PubMed ID: 19464172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
    Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
    J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and opioid receptor activity of indolopropellanes.
    Li F; Gaob L; Yin C; Chen J; Liu J; Xie X; Zhang A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4603-6. PubMed ID: 19595591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
    Bennett MA; Murray TF; Aldrich JV
    J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
    Zhao M; Wang JY; Jia H; Tang JS
    Brain Res; 2006 Mar; 1076(1):68-77. PubMed ID: 16476416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Has the sun set on kappa3-opioid receptors?
    Connor M; Kitchen I
    Br J Pharmacol; 2006 Feb; 147(4):349-50. PubMed ID: 16402044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atomoxetine in the treatment of ADHD].
    Myhr K
    Tidsskr Nor Laegeforen; 2006 Feb; 126(4):457-8. PubMed ID: 16477285
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
    Park HS; Lee HY; Kim YH; Park JK; Zvartau EE; Lee H
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3609-13. PubMed ID: 16650985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid profiles of Cys2-containing enkephalin analogues.
    Pencheva N; Milanov P; Vezenkov L; Pajpanova T; Naydenova E
    Eur J Pharmacol; 2004 Sep; 498(1-3):249-56. PubMed ID: 15364002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.